Tetraxim

Protection against diphtheria, tetanus, pertussis & poliomyelitis in childn from the age of 2 mth.

IM 2 inj at an interval of 2 mth (1 at the age of 2 mth & 1 at the age of 4 mth), followed by 1 booster inj at the age of 11 mth, then another booster inj at the age of 6 yr; booster vaccination for childn 11-13 yr who did not receive a vaccine containing the pertussis valence at normal conc at the age of 6 yr. Alternatively, 3 inj at an interval of 1 or 2 mth from the age of 2 mth, followed by 1 booster inj w/in the 2nd yr of life, & another booster inj between 4-13 yr of age.

Hypersensitivity to any of the vaccine components; glutaraldehyde, neomycin, streptomycin, or polymyxin B; pertussis vaccine (acellular or whole cell). Allergic reaction after an inj of the same vaccine or a vaccine containing the same substances. Evolving encephalopathy. History of encephalopathy w/in 7 days of a previous dose of pertussis vaccine (acellular or whole cell). Postpone vaccination in case of fever or acute disease.

Must never be injected intravascularly. Immune response may be diminished in childn w/ poor immune defences, or if treated w/ corticosteroids, cytotoxic medicines, RT or other medicines that may weaken the immune system. Wait until the end of treatment or disease before vaccinating. Vaccination is recommended in patients w/ chronic immunodeficiency eg, HIV infection. Risk of bleeding during IM administration in childn w/ blood disorders (eg, thrombocytopenia) or clotting disorders. Carefully evaluate decision to give further doses in case of the following events after a previous Tetraxim vaccination: fever ≥40°C (not due to another identifiable cause), collapse or shock-like state w/ hypotonic-hyporesponsive episode, &/or persistent inconsolable crying lasting ≥3 hr, occurring w/in 48 hr of vaccination; convulsions w/ or w/o fever, occurring w/in 3 days of vaccination. Monitor temp for 48 hr after vaccination in childn w/ history of febrile convulsions unrelated to a previous vaccination. Administer Tetraxim & HIB conjugate vaccine into 2 separate inj sites & on different days in case of oedema in the lower limbs following inj of HIB-containing vaccine. Contains phenylalanine, which may be harmful for patients w/ phenylketonuria. Caution in childn w/ history of Guillain-Barré syndrome or brachial neuritis following receipt of prior vaccine containing tetanus toxoid; current, or history of, allergic reaction following Tetraxim inj; adolescents of childbearing potential.

Loss of appetite; nervousness, irritability; abnormal crying; somnolence; headache; vomiting; myalgia; inj site erythema, pain, oedema; fever ≥38°C; malaise. Insomnia, sleep disorder; diarrhoea; inj site induration.

Administer in 2 separate inj sites if to be vaccinated simultaneously w/ another vaccine.

Vaccines, Antisera & Immunologicals

J07CA02 - diphtheria-pertussis-poliomyelitis-tetanus ; Belongs to the class of combined bacterial and viral vaccines.

P₁S₁S₃, A